Beyond Genomics Inc has entered into an evaluation agreement with GlaxoSmithKline to apply Beyond Genomics' (BG) Systems Biology approach to elucidate disease pathways and identify protein and metabolite markers (Biosystem Markers) of disease state and drug response. The goal is to discover novel Biosystem Markers, and to better understand proteins and metabolites that may play critical roles in mediating disease states and response to drugs. Financial and additional deal terms were not disclosed.

"We are excited that GlaxoSmithKline, a world leader in pharmaceutical innovation, is evaluating our Systems Biology capabilities," said N. Stephen Ober, President of Beyond Genomics.

Dr. Ober added, "We feel that BG's Systems Biology approach can maximize the value of research and development portfolios by providing knowledge for new indications and novel pathway information related to disease and drug response."

BG's technologies include a number of high-throughput, next generation genomic, proteomic and metabolomic platforms. Biosystem Markers identified by BG are further characterized to determine their roles in disease and drug response. The company also employs proprietary pattern recognition, clustering and data mining software (BioSystematics) to integrate and analyze all relevant data to generate new insights into the mechanisms of disease and drug response.